Australia To Consider Removal Of Popular Painkiller From OTC
This article was originally published in PharmAsia News
Australia authorities are considering a move to remove over-the-counter status for one of the country's favorite painkillers, Nurofen's Nurofen Plus (ibuprofen, codeine phosphate). An advisory panel has set a June meeting to consider the proposal to move Nurofen Plusand similar painkillers containing codeine to prescription-only status. Physician and pharmacy groups say the move is too drastic and suggest an alternative could be limiting the size of packets of the drugs. The nation's leading medical journal reported misuse of such drugs, particularly Nurofen Plus, is a significant problem in the country. (Click here for more
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.